In Vitro and in Vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring

Jiyun Chen, Jin Hwang Dong, Kiwon Chung, Casey E. Bohl, Scott J. Fisher, Duane Miller, James T. Dalton

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We recently reported two nonsteroidal androgen receptor (AR) ligands that demonstrate tissue-selective pharmacological activity, identifying these S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl) -propionamide analogs as the first members of a new class of drugs known as selective androgen receptor modulators. The purpose of these studies was to explore additional structure-activity relationships of selective androgen receptor modulators to enhance their AR binding affinity, AR-mediated transcriptional activation, and in vivo pharmacological activity. The AR binding affinity (Ki) of 29 novel synthetic AR ligands was determined by a radioligand competitive binding assay and ranged from 1.0-51 nM. Compounds with electron-withdrawing substituents at the para- and meta-positions of the B-ring demonstrated the highest AR binding affinity. The AR-mediated transcriptional activation was determined using a cotransfection assay in CV-1 cells. Most compounds with two substituents in the B-ring maintained or improved their functional activity in vitro. However, compounds with three halogen substituents exhibited significant regioselectivity. Fifteen compounds were selected to examine their pharmacological activity in castrated rats. In vivo pharmacological activity and selectivity were significantly changed by structural modification in the B-ring. Compounds with halogen groups at the para- and meta-positions of the B-ring displayed the highest pharmacological activity. Incorporating substituents at the ortho-position of the B-ring resulted in poor pharmacological activity. In vitro and in vivo agonist activities were partially correlated. In conclusion, novel selective androgen receptor modulators with improved in vivo pharmacological activity can be designed and synthesized based on the structure-activity relationship identified in these studies.

Original languageEnglish (US)
Pages (from-to)5444-5454
Number of pages11
JournalEndocrinology
Volume146
Issue number12
DOIs
StatePublished - Dec 1 2005

Fingerprint

Androgen Receptors
Structure-Activity Relationship
Ligands
Pharmacology
Halogens
Transcriptional Activation
Testosterone Congeners
Artificial Receptors
In Vitro Techniques
Competitive Binding
Electrons

All Science Journal Classification (ASJC) codes

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

In Vitro and in Vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. / Chen, Jiyun; Dong, Jin Hwang; Chung, Kiwon; Bohl, Casey E.; Fisher, Scott J.; Miller, Duane; Dalton, James T.

In: Endocrinology, Vol. 146, No. 12, 01.12.2005, p. 5444-5454.

Research output: Contribution to journalArticle

Chen, Jiyun ; Dong, Jin Hwang ; Chung, Kiwon ; Bohl, Casey E. ; Fisher, Scott J. ; Miller, Duane ; Dalton, James T. / In Vitro and in Vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. In: Endocrinology. 2005 ; Vol. 146, No. 12. pp. 5444-5454.
@article{78fadb30f5bd43db820020c5eb441b27,
title = "In Vitro and in Vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring",
abstract = "We recently reported two nonsteroidal androgen receptor (AR) ligands that demonstrate tissue-selective pharmacological activity, identifying these S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl) -propionamide analogs as the first members of a new class of drugs known as selective androgen receptor modulators. The purpose of these studies was to explore additional structure-activity relationships of selective androgen receptor modulators to enhance their AR binding affinity, AR-mediated transcriptional activation, and in vivo pharmacological activity. The AR binding affinity (Ki) of 29 novel synthetic AR ligands was determined by a radioligand competitive binding assay and ranged from 1.0-51 nM. Compounds with electron-withdrawing substituents at the para- and meta-positions of the B-ring demonstrated the highest AR binding affinity. The AR-mediated transcriptional activation was determined using a cotransfection assay in CV-1 cells. Most compounds with two substituents in the B-ring maintained or improved their functional activity in vitro. However, compounds with three halogen substituents exhibited significant regioselectivity. Fifteen compounds were selected to examine their pharmacological activity in castrated rats. In vivo pharmacological activity and selectivity were significantly changed by structural modification in the B-ring. Compounds with halogen groups at the para- and meta-positions of the B-ring displayed the highest pharmacological activity. Incorporating substituents at the ortho-position of the B-ring resulted in poor pharmacological activity. In vitro and in vivo agonist activities were partially correlated. In conclusion, novel selective androgen receptor modulators with improved in vivo pharmacological activity can be designed and synthesized based on the structure-activity relationship identified in these studies.",
author = "Jiyun Chen and Dong, {Jin Hwang} and Kiwon Chung and Bohl, {Casey E.} and Fisher, {Scott J.} and Duane Miller and Dalton, {James T.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1210/en.2005-0732",
language = "English (US)",
volume = "146",
pages = "5444--5454",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - In Vitro and in Vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring

AU - Chen, Jiyun

AU - Dong, Jin Hwang

AU - Chung, Kiwon

AU - Bohl, Casey E.

AU - Fisher, Scott J.

AU - Miller, Duane

AU - Dalton, James T.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - We recently reported two nonsteroidal androgen receptor (AR) ligands that demonstrate tissue-selective pharmacological activity, identifying these S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl) -propionamide analogs as the first members of a new class of drugs known as selective androgen receptor modulators. The purpose of these studies was to explore additional structure-activity relationships of selective androgen receptor modulators to enhance their AR binding affinity, AR-mediated transcriptional activation, and in vivo pharmacological activity. The AR binding affinity (Ki) of 29 novel synthetic AR ligands was determined by a radioligand competitive binding assay and ranged from 1.0-51 nM. Compounds with electron-withdrawing substituents at the para- and meta-positions of the B-ring demonstrated the highest AR binding affinity. The AR-mediated transcriptional activation was determined using a cotransfection assay in CV-1 cells. Most compounds with two substituents in the B-ring maintained or improved their functional activity in vitro. However, compounds with three halogen substituents exhibited significant regioselectivity. Fifteen compounds were selected to examine their pharmacological activity in castrated rats. In vivo pharmacological activity and selectivity were significantly changed by structural modification in the B-ring. Compounds with halogen groups at the para- and meta-positions of the B-ring displayed the highest pharmacological activity. Incorporating substituents at the ortho-position of the B-ring resulted in poor pharmacological activity. In vitro and in vivo agonist activities were partially correlated. In conclusion, novel selective androgen receptor modulators with improved in vivo pharmacological activity can be designed and synthesized based on the structure-activity relationship identified in these studies.

AB - We recently reported two nonsteroidal androgen receptor (AR) ligands that demonstrate tissue-selective pharmacological activity, identifying these S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl) -propionamide analogs as the first members of a new class of drugs known as selective androgen receptor modulators. The purpose of these studies was to explore additional structure-activity relationships of selective androgen receptor modulators to enhance their AR binding affinity, AR-mediated transcriptional activation, and in vivo pharmacological activity. The AR binding affinity (Ki) of 29 novel synthetic AR ligands was determined by a radioligand competitive binding assay and ranged from 1.0-51 nM. Compounds with electron-withdrawing substituents at the para- and meta-positions of the B-ring demonstrated the highest AR binding affinity. The AR-mediated transcriptional activation was determined using a cotransfection assay in CV-1 cells. Most compounds with two substituents in the B-ring maintained or improved their functional activity in vitro. However, compounds with three halogen substituents exhibited significant regioselectivity. Fifteen compounds were selected to examine their pharmacological activity in castrated rats. In vivo pharmacological activity and selectivity were significantly changed by structural modification in the B-ring. Compounds with halogen groups at the para- and meta-positions of the B-ring displayed the highest pharmacological activity. Incorporating substituents at the ortho-position of the B-ring resulted in poor pharmacological activity. In vitro and in vivo agonist activities were partially correlated. In conclusion, novel selective androgen receptor modulators with improved in vivo pharmacological activity can be designed and synthesized based on the structure-activity relationship identified in these studies.

UR - http://www.scopus.com/inward/record.url?scp=27844550753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844550753&partnerID=8YFLogxK

U2 - 10.1210/en.2005-0732

DO - 10.1210/en.2005-0732

M3 - Article

VL - 146

SP - 5444

EP - 5454

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 12

ER -